Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4481-4488

  Kuroki, Masahide ^a   Shirasu, Naoto ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cancer therapy; Monoclonal antibody; Novel treatment strategy; Review; Tumor targeting; Tumor associated antigen

Indexed keywords

ANTIBODY CONJUGATE; CHIMERIC ANTIGEN RECEPTOR; HYBRID PROTEIN; POXVIRUS VECTOR; TUMOR ANTIGEN; VIRUS VECTOR; BISPECIFIC ANTIBODY; CANCER ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HLA SYSTEM; HUMAN; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHOTODYNAMIC THERAPY; SONODYNAMIC THERAPY; TARGET CELL; THERAPY; TISSUE SPECIFICITY; TREATMENT OUTCOME; TUMOR ESCAPE; CANCER THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NOVEL TREATMENT STRATEGY; PHOTOCHEMOTHERAPY; REVIEW; TUMOR TARGETING; TUMOR-ASSOCIATED ANTIGEN;

CANCER THERAPY; MONOCLONAL ANTIBODY; NOVEL TREATMENT STRATEGY; REVIEW; TUMOR TARGETING; TUMOR-ASSOCIATED ANTIGEN;

ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PHOTOCHEMOTHERAPY; RECEPTORS, ANTIGEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84908692057     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Plaetzer K, Krammer B, Berlanda J, Berr F and Kiesslich T: Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 24: 259-268, 2009.
2. Rosenthal I, Sostaric JZ and Riesz P: Sonodynamic therapy-a review of the synergistic effects of drugs and ultrasound. Ultrason Sonochem 11: 349-363, 2004.
3. Kuroki M, Ueno A, Matsumoto H, Abe H, Li T, Imakiire T, Yamauchi Y, Uno K, Shirota K and Shibaguchi H: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res 22: 4255-4264, 2002.
4. Varghese S and Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967-978, 2002.
5. Kirn D: Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1: 525-538, 2001.
6. Kuroki Ma, Huang J, Shibaguchi H, Tanaka T, Zhao j, Luo N, Hachimine K, Kinugasa T, Maekawa S, Enatsu S, Hamanaka W, Fukami T and Kuroki Mo: Possible application of antibodies or their genes in cancer therapy. Anticancer Res 26: 4019-4025, 2006.
7. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K and Ledbetter JA: Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71: 13-29, 1988.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
9. Bradley AM, Devine M and DeRemer D: Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm 70: 589-597, 2013.
10. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR and Walter RB: Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123: 554-561, 2014.
11. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC and Byrd JC: Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20: 272-279, 2006.
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
13. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PYand Lum LG: Anti-CD3xanti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12: 183-190, 2006.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350: 2335-2342, 2004.
15. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E and Primus FJ: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60: 4475-4484, 2000.
16. Khare PD, Shao-Xi L, Kuroki Mo, Hirose Y, Arakawa F, Nakamura K, Tomita Y and Kuroki, Ma: Specificaly targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retrovector displaying single chain variable fragmented (scFv) antibody to CEA and carrying inducible nitric oxide synthase (iNOS) gene. Cancer Res 61: 370-375, 2001.
17. Haisma HJ, Pinedo HM, Rijswijk A, der Muelen Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR and Curiel DT: Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 6: 1469-1474, 1999.
18. Presta LG: Engineering antibodies for therapy. Curr Pharm Biotechnol 3: 237-256, 2002.
19. Beck A and Reichert JM: Antibody-drug conjugates: Present and future. MAbs 6: 15-17, 2014.
20. Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ and Sgouros G: Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. J Nucl Med 54: 1535-1542, 2013.
21. Shirasu N, Nam SO and Kuroki M: Tumor-targeted photodynamic therapy. Anticancer Res 33: 2823-2831, 2013.
22. Tsuru H, Shibaguchi H, Kuroki Mo, Yamashita Y and Kuroki Ma: Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer. Free Radic Biol Med 53: 464-472, 2012.
23. Duska LR, Hamblin MR, Miller JL and Hasan T: Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst 91: 1557-1563, 1999.
24. Wu AM and Senter PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146, 2005.
25. Savellano MD and Hasan T: Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin Cancer Res 11: 1658-1668, 2005.
26. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL and Kobayashi H: Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17: 1685-1691, 2011.
27. Shirasu N, Yamada H, Shibaguchi H, Kuroki Mo and Kuroki Ma: Potent and specific effect of CEA-targeted photoimmunotherapy. Int J Cancer, doi: 10.1002/ijc.28907, 2014.
28. Kuroki Ma, Hachimine K, Abe H, Shibaguchi H, Kuroki Mo, Maekawa S, Yanagisawa J, Kinugasa T, Tanaka T and Yamashita Y: Sonodynamic therapy of cancer using novel sonosensitizers. Anticancer Res 27: 3673-3677, 2007.
29. Abe H, Kuroki Mo, Tachibana K, Li T, Awasthi A, Ueno A, Matsumoto H, Imakiire T, Yamauchi Y, Yamada H, Ariyoshi A and Kuroki MA: Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res 22: 1575-1580, 2002.
30. Kuroki Ma, Kuroki Mo, Shibaguchi H, Badran A, Hachimine K, Zhang J and Kinugasa T: Strategies to endow cytotoxic T-lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen. Tumor Biol 25: 208-216, 2004.
31. Bolhuis RL, Sturm E and Braakman E: T-cell targeting in cancer therapy. Cancer Immunol Immunother 1991: 34: 1-8, 1991.
32. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A and Krause SW: T-lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27: 1107-1115, 2013.
33. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR and Walter RB: Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123: 554-561, 2014.
34. Penichet ML and Morrison SL: Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248: 91-101, 2001.
35. Müller D: Antibody-cytokine fusion proteins for cancer immunotherapy: An Update on Recent Developments. BioDrugs 28: 123-131, 2014.
36. List T and Neri D: Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 5: 29- 45, 2013.
37. Liao S, Khare PD, Arakawa F, Kuroki Mo, Hirose Y, Fujimura S, Tomita Y and Kuroki Ma: Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res 21: 1673-1680, 2001.
38. Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML and Ljubimova JY: Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release 171: 322-329, 2013.
39. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F and Kurosawa Y: Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149: 960-968, 1987.
40. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH and McArthur JG: Impact of chimeric immune receptor extracellular protein domains on T-cell function. Gene Ther 6: 412-419, 1999.
41. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ and Darcy PK: Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors co-delivering CD28 co-stimulation. J Immunol 169: 5780-5786, 2002.
42. Arakawa F, Shibaguchi H, Xu Z and Kuroki Ma: Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-shain anti-CEA activity. Anticancer Res 22: 4285-4290, 2002.
43. Maus MV, Grupp SA, Porter DL and June CH: Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625-2635, 2014.
44. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE and Rosenberg SA: Donor-derived CD19-targeted T-cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-4139, 2013.
45. Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kuhlcke K, Westwood N, Thistlethwaite F, Hawkins RE and Gilham DE: Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother 63: 133-145, 2014.
46. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE and Gilham DE: CAR T-cells: driving the road from the laboratory to the clinic. Immunol Rev 257: 91-106, 2014.
47. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M and Ali A: Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 18: 771-781, 2012
48. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 30: 658-670, 2012.
49. Conner J, Braidwood L and Brown SM: A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther 15: 1579-1592, 2008.
50. Miest TS and Cattaneo R: New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 12: 23-34, 2014.
51. Menotti L, Cerretani A and Campadelli-Fiume G: A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 80: 5531-5539, 2006.
52. Baek H, Uchida H, Jun K, Kim JH, Kuroki M, Cohen JB, Glorioso JC and Kwon H: Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol Ther 19: 507-514, 2011.
53. Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB and Glorioso JC: Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther 21: 561-569, 2013.
54. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y and Szalay AA: Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8: 141-151, 2009.
55. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA: Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 106: 12915-12920, 2009.
56. Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, Ehrig K, Stritzker J, Mundt AJ and Szalay AA: Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int J Cancer 133: 2989-2999, 2013.